Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 6Phase 1/2 2Phase 1 2Phase NA 1

Status

Completed 4Terminated 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia 10Prostatic Neoplasms 6Lymphoma 6Burkitt Lymphoma 4Leukemia, Biphenotypic, Acute 3Anemia, Refractory, with Excess of Blasts 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory 2Prostate Cancer Metastatic 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lipomatosis, Multiple Symmetrical 1Lipoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Drug-Related Side Effects and Adverse Reactions 1Dendritic Cell Sarcoma, Interdigitating 1Cardiotoxicity 1

Interventions

Prednisone 53Radiotherapy 52Docetaxel 51Leuprolide 48Goserelin 47bicalutamide 45enzalutamide 28acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 27Androgen Antagonists 27Flutamide 24Triptorelin Pamoate 22apalutamide 18Gonadotropin-Releasing Hormone 18Abiraterone Acetate 17Radiation 15abiraterone 14Zoledronic Acid 14Magnetic Resonance Spectroscopy 13gallium 68 PSMA-11 12Prednisolone 11luprolide acetate gel depot 10darolutamide 9Radiosurgery 9cabazitaxel 8Standard of Care 8Specimen Handling 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 8Estramustine 8Dexamethasone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Prostatic Neoplasms × Hydrocortisone × Clear all
NCT06136650 2026-05-27

MK-5684-004

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,314 enrolled
Genitourinary

Prostatic Neoplasms

NCT00027859 2023-06-15

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

Eastern Cooperative Oncology Group

Phase 3 Completed
Genitourinary

Prostatic Neoplasms

NCT00002855 2018-10-31

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

M.D. Anderson Cancer Center

Phase 3 Completed
306 enrolled
Genitourinary

Prostatic Neoplasms

NCT00002760 2016-06-28

Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Completed
260 enrolled
Genitourinary

Prostatic Neoplasms

NCT00705822 2010-11-30

PROSTATA

Sanofi

Phase 3 Terminated
54 enrolled
Genitourinary

Prostatic Neoplasms

NCT00002881 2010-11-09

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 3 Completed
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡